CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aligos Therapeutics, Inc. - ALGS CFD

0.6938
0.76%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0098
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Aligos Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.6886
Open* 0.7076
1-Year Change* -27.71%
Day's Range* 0.6938 - 0.7277
52 wk Range 0.54-2.41
Average Volume (10 days) 77.27K
Average Volume (3 months) 1.65M
Market Cap 48.86M
P/E Ratio -100.00K
Shares Outstanding 74.93M
Revenue 16.39M
EPS -1.90
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 0.6938 -0.0138 -1.95% 0.7076 0.7277 0.6938
Nov 30, 2023 0.6886 -0.0345 -4.77% 0.7231 0.7231 0.6776
Nov 29, 2023 0.6876 0.0100 1.48% 0.6776 0.7116 0.6776
Nov 28, 2023 0.6924 -0.0052 -0.75% 0.6976 0.7276 0.6680
Nov 27, 2023 0.7276 0.0090 1.25% 0.7186 0.7353 0.7136
Nov 24, 2023 0.7121 0.0645 9.96% 0.6476 0.7321 0.6476
Nov 22, 2023 0.6674 -0.0258 -3.72% 0.6932 0.7230 0.6674
Nov 21, 2023 0.6486 -0.0290 -4.28% 0.6776 0.6776 0.6485
Nov 20, 2023 0.6876 0.0300 4.56% 0.6576 0.7076 0.6476
Nov 17, 2023 0.6576 -0.0401 -5.75% 0.6977 0.6977 0.6476
Nov 16, 2023 0.6196 0.0109 1.79% 0.6087 0.6535 0.6087
Nov 15, 2023 0.6076 -0.0298 -4.68% 0.6374 0.6670 0.6076
Nov 14, 2023 0.5886 -0.0078 -1.31% 0.5964 0.6186 0.5726
Nov 13, 2023 0.5776 -0.1500 -20.62% 0.7276 0.7276 0.5526
Nov 10, 2023 0.6769 -0.0657 -8.85% 0.7426 0.7462 0.6401
Nov 9, 2023 0.7576 0.0100 1.34% 0.7476 0.7576 0.7314
Nov 8, 2023 0.7089 -0.0219 -3.00% 0.7308 0.7450 0.6868
Nov 7, 2023 0.7326 -0.0050 -0.68% 0.7376 0.7465 0.7152
Nov 6, 2023 0.7568 -0.0408 -5.12% 0.7976 0.8128 0.7449
Nov 3, 2023 0.7578 0.0202 2.74% 0.7376 0.7579 0.7276

Aligos Therapeutics, Inc. Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Aligos Therapeutics Inc Earnings Release
Q4 2023 Aligos Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 13.907 4.359 0 0 0
Total Operating Expense 111.487 132.68 97.834 54.043 14.094
Selling/General/Admin. Expenses, Total 26.41 28.527 17.944 10.005 3.205
Research & Development 85.077 104.153 79.89 43.354 10.39
Depreciation / Amortization 0.684 0.066
Unusual Expense (Income) 0.433
Operating Income -97.58 -128.321 -97.834 -54.043 -14.094
Interest Income (Expense), Net Non-Operating 1.521 0.242 1.256 1.562 0.163
Other, Net 0.119 -0.11 -11.804 0.302 -0.002
Net Income Before Taxes -95.94 -128.189 -108.382 -52.179 -13.933
Net Income After Taxes -96.046 -128.332 -108.543 -52.264 -13.933
Net Income Before Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
Net Income -96.046 -128.332 -108.543 -52.264 -13.933
Income Available to Common Excl. Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
Income Available to Common Incl. Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
Diluted Net Income -96.046 -128.332 -108.543 -52.264 -13.933
Diluted Weighted Average Shares 42.6952 39.8554 36.6063 36.8902 36.8902
Diluted EPS Excluding Extraordinary Items -2.24957 -3.21994 -2.96515 -1.41675 -0.37769
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.24957 -3.21994 -2.96515 -1.41675 -0.36595
Revenue 13.907 4.359
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 6.886 2.723 3.537 4.106 3.693
Revenue 6.886 2.723 3.537 4.106 3.693
Total Operating Expense 26.027 26.641 26.219 23.054 24.086
Selling/General/Admin. Expenses, Total 6.246 5.006 7.119 5.263 7.576
Research & Development 16.781 18.135 19.1 17.791 16.51
Operating Income -19.141 -23.918 -22.682 -18.948 -20.393
Interest Income (Expense), Net Non-Operating 0.955 0.748 0.757 0.466 0.212
Other, Net 0.152 0.254 0.088 -0.182 0.304
Net Income Before Taxes -18.034 -22.916 -21.837 -18.664 -19.877
Net Income After Taxes -18.791 -22.955 -21.886 -18.621 -19.924
Net Income Before Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
Net Income -18.791 -22.955 -21.886 -18.621 -19.924
Income Available to Common Excl. Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
Income Available to Common Incl. Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
Diluted Net Income -18.791 -22.955 -21.886 -18.621 -19.924
Diluted Weighted Average Shares 43.2155 42.9101 42.8377 42.7619 42.6656
Diluted EPS Excluding Extraordinary Items -0.43482 -0.53496 -0.5109 -0.43546 -0.46698
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.3897 -0.48194 -0.5109 -0.43546 -0.46698
Unusual Expense (Income) 3 3.5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 133.545 204.424 250.017 120.226 92.369
Cash and Short Term Investments 125.827 190.734 243.513 117.663 90.852
Cash & Equivalents 81.347 186.816 220.383 69.565 24.035
Short Term Investments 44.48 3.918 23.13 48.098 66.817
Other Current Assets, Total 7.718 13.69 6.504 2.563 1.517
Total Assets 146.693 235.369 265.302 146.52 107.731
Property/Plant/Equipment, Total - Net 12.514 14.969 14.908 16.087 15.184
Property/Plant/Equipment, Total - Gross 22.082 22.231 19.151 17.595 15.296
Accumulated Depreciation, Total -9.568 -7.262 -4.243 -1.508 -0.112
Long Term Investments 0 15.11 10.019 0
Other Long Term Assets, Total 0.634 0.866 0.377 0.188 0.178
Total Current Liabilities 33.129 38.957 30.274 13.818 7.489
Accounts Payable 4.737 3.015 3.313 3.767 2.977
Accrued Expenses 17.535 26.652 18.27 8.702 4.389
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.108 0.138 0.064 0.074 0.01
Other Current Liabilities, Total 10.749 9.152 8.627 1.275 0.113
Total Liabilities 42.793 50.638 45.263 29.332 20.96
Total Long Term Debt 0.23 0.394 0.509 3.352 0.026
Long Term Debt 0 0.133 0.379 3.174 0
Capital Lease Obligations 0.23 0.261 0.13 0.178 0.026
Other Liabilities, Total 9.434 11.287 14.48 12.162 13.445
Total Equity 103.9 184.731 220.039 117.188 86.771
Redeemable Preferred Stock 0 0 182.079 100.519
Common Stock 0.004 0.004 0.004 0.004 0.003
Additional Paid-In Capital 502.613 487.347 394.963 1.417 0.179
Retained Earnings (Accumulated Deficit) -399.118 -303.072 -174.74 -66.197 -13.933
Other Equity, Total 0.401 0.452 -0.188 -0.115 0.003
Total Liabilities & Shareholders’ Equity 146.693 235.369 265.302 146.52 107.731
Total Common Shares Outstanding 42.9401 42.6941 39.6986 36.8902 36.8902
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 74.643 94.243 109.429 133.545 150.093
Cash and Short Term Investments 70.429 90.838 103.516 125.827 142.304
Cash & Equivalents 70.429 90.828 78.671 81.347 86.44
Short Term Investments 0 0.01 24.845 44.48 55.864
Other Current Assets, Total 4.214 3.405 5.913 7.718 7.789
Total Assets 85.852 106.13 121.738 146.693 164.069
Property/Plant/Equipment, Total - Net 10.586 11.263 11.677 12.514 13.323
Property/Plant/Equipment, Total - Gross 21.318 21.689 21.699 22.082 22.369
Accumulated Depreciation, Total -10.732 -10.426 -10.022 -9.568 -9.046
Other Long Term Assets, Total 0.623 0.624 0.632 0.634 0.653
Total Current Liabilities 22.468 27.225 28.079 33.129 30.541
Accounts Payable 2.941 3.241 2.822 4.737 2.931
Accrued Expenses 14.253 15.502 15.807 17.535 15.748
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.058 0.064 0.108 0.108 0.138
Other Current Liabilities, Total 5.216 8.418 9.342 10.749 11.724
Total Liabilities 31.031 36.495 36.988 42.793 42.056
Total Long Term Debt 0.188 0.203 0.205 0.23 0.174
Capital Lease Obligations 0.188 0.203 0.205 0.23 0.174
Other Liabilities, Total 8.375 9.067 8.704 9.434 11.341
Total Equity 54.821 69.635 84.75 103.9 122.013
Redeemable Preferred Stock 0
Common Stock 0.004 0.004 0.004 0.004 0.004
Additional Paid-In Capital 513.225 509.998 506.32 502.613 499.082
Retained Earnings (Accumulated Deficit) -458.905 -440.864 -422.073 -399.118 -377.232
Other Equity, Total 0.497 0.497 0.499 0.401 0.159
Total Liabilities & Shareholders’ Equity 85.852 106.13 121.738 146.693 164.069
Total Common Shares Outstanding 43.5026 43.5026 42.9401 42.9401 45.9079
Long Term Debt 0
Long Term Investments 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -96.046 -128.332 -108.543 -52.264 -13.933
Cash From Operating Activities -79.389 -115.662 -74.263 -46.767 -6.049
Cash From Operating Activities 2.306 3.019 2.735 2.299 1.291
Non-Cash Items 15.903 14.302 15.482 -0.473 1.708
Cash Taxes Paid 0 0 0.001 0
Cash Interest Paid 0 0 0 0.006 0
Changes in Working Capital -1.552 -4.651 16.063 3.671 4.885
Cash From Investing Activities -26.293 3.022 32.755 6.791 -69.289
Capital Expenditures -0.943 -0.892 -2.064 -2.786 -2.516
Other Investing Cash Flow Items, Total -25.35 3.914 34.819 9.577 -66.773
Cash From Financing Activities 0.164 78.677 192.348 85.532 99.885
Issuance (Retirement) of Stock, Net 0.225 79.631 196.522 85.575 94.885
Issuance (Retirement) of Debt, Net -0.061 -0.079 -0.058 -0.043 5
Net Change in Cash -105.518 -33.963 150.84 45.556 24.547
Financing Cash Flow Items -0.875 -4.116
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -22.955 -96.046 -74.16 -55.539 -35.615
Cash From Operating Activities -22.387 -79.389 -62.606 -45.469 -20.434
Cash From Operating Activities 0.454 2.306 1.784 1.246 0.676
Non-Cash Items 3.787 15.903 12.187 8.397 4.102
Cash Interest Paid 0 0 0
Changes in Working Capital -3.673 -1.552 -2.417 0.427 10.403
Cash From Investing Activities 19.993 -26.293 -37.897 -70.38 -60.404
Capital Expenditures -0.007 -0.943 -0.852 -0.849 -0.515
Other Investing Cash Flow Items, Total 20 -25.35 -37.045 -69.531 -59.889
Cash From Financing Activities -0.001 0.164 0.043 0.062 -0.021
Financing Cash Flow Items 0 0
Issuance (Retirement) of Stock, Net 0.023 0.225 0.131 0.122 0.01
Issuance (Retirement) of Debt, Net -0.024 -0.061 -0.088 -0.06 -0.031
Net Change in Cash -2.395 -105.518 -100.46 -115.787 -80.859
Cash Taxes Paid 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
EcoR1 Capital, LLC Hedge Fund 5.4961 3948360 0 2023-06-30 LOW
Vivo Capital, LLC Venture Capital 4.9374 3547030 0 2023-06-30 LOW
Tang Capital Management, LLC Hedge Fund 4.634 3329048 -95752 2023-06-30 MED
Roche Holding AG Holding Company 4.3045 3092340 0 2023-04-27
Versant Ventures Venture Capital 3.23 2320381 0 2023-06-30 LOW
HHLR Advisors, Ltd. Investment Advisor/Hedge Fund 3.2152 2309764 0 2023-06-30 MED
Blatt (Lawrence M) Individual Investor 2.9519 2120633 610277 2023-10-25
Baker Bros. Advisors LP Hedge Fund 2.8903 2076400 0 2023-06-30 LOW
Beigelman (Leonid) Individual Investor 2.1024 1510352 0 2023-04-27
Adage Capital Management, L.P. Hedge Fund 1.7028 1223278 0 2023-06-30 LOW
BofA Global Research (US) Research Firm 1.6021 1150945 3162 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.3846 994712 -21969 2023-06-30 LOW
Newtyn Management, LLC Hedge Fund 1.2528 900000 -121461 2023-06-30 MED
RBC Capital Markets Wealth Management Research Firm 1.1693 840030 795328 2023-06-30 LOW
Pivotal Bioventure Partners Investment Advisor LLC Venture Capital 1.0345 743215 0 2023-06-30 LOW
SilverArc Capital Management, LLC Hedge Fund 0.8796 631887 0 2023-06-30 HIGH
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.7861 564715 0 2023-06-30 MED
Renaissance Technologies LLC Hedge Fund 0.5993 430555 -22305 2023-06-30 HIGH
Symons (Julian A) Individual Investor 0.5485 394064 0 2023-04-27
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.3866 277728 -7138 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aligos Therapeutics, Inc. Company profile

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).

Industry: Biotechnology & Medical Research (NEC)

One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

BTC/USD

39,631.50 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading